氨甲酰化高密度脂蛋白与2型糖尿病患者的死亡结局
本研究在1517例2型糖尿病患者中检测基线血浆氨甲酰化高密度脂蛋白(HDL)水平,随访中位14年。结果显示氨甲酰化HDL水平升高与全因死亡及心血管、肾脏、感染和癌症相关死亡独立相关,且能提升死亡风险预测模型的区分度。
要点
- 氨甲酰化HDL水平升高与2型糖尿病患者全因死亡风险增加独立相关。
- 氨甲酰化HDL也与心血管、肾脏、感染及癌症相关死亡风险增加相关。
- 将氨甲酰化HDL加入多变量模型可小幅提升全因死亡预测的C指数。
核心结论
- 氨甲酰化HDL水平升高是2型糖尿病患者全因死亡及病因别死亡的独立危险因素。
研究设计与样本
- 研究纳入1517例2型糖尿病患者,采用ELISA法检测基线血浆氨甲酰化HDL水平。
- 中位随访14年,主要结局为全因死亡,次要结局为心血管、肾脏、感染及癌症相关死亡。
主要发现
- 随访期间292例患者死亡,死亡率为14.5/1000人年。
- 死亡患者基线氨甲酰化HDL水平高于存活者(46.1 ± 17.8 µg/mL vs. 32.9 ± 10.7 µg/mL;P < 0.01)。
- 氨甲酰化HDL第三四分位组死亡风险HR为2.11(95% CI 1.40-3.17;P < 0.001),第四四分位组HR为6.55(95% CI 4.67-9.77;P < 0.001)。
- 校正传统危险因素后,氨甲酰化HDL升高与全因死亡独立相关(HR 1.39;95% CI 1.28-1.52;P < 0.001),也与所有病因别死亡相关。
- 将氨甲酰化HDL加入多变量模型后,全因死亡预测的C指数从0.78提升至0.80(P < 0.001),并显著改善净重分类指数和综合判别改善指数。
临床怎么用
- 氨甲酰化HDL或可作为2型糖尿病患者死亡风险分层的潜在生物标志物。
- 在传统风险因素基础上,检测氨甲酰化HDL可能小幅提升全因死亡风险预测能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Carbamylation is part of the aging process and causes adverse changes in the structure and function of proteins. Lipoproteins are subjected to carbamylation. We investigated the usefulness of carbamylated HDL as a prognostic indicator of survival in patients with type 2 diabetes and the association with mortality outcomes. RESEARCH DESIGN AND METHODS: Baseline plasma carbamylated HDL was measured by ELISA in a cohort of 1,517 patients with type 2 diabetes. The primary outcome was all-cause mortality, and the secondary outcomes were cause-specific deaths, including cardiovascular, renal, infection, and cancer related. RESULTS: Over a median follow-up of 14 years, 292 patients died, and the mortality rate was 14.5 per 1,000 person-years. Plasma carbamylated HDL level was higher in those with a fatal outcome (46.1 ± 17.8 µg/mL vs. 32.9 ± 10.7; P < 0.01). Patients in the third (hazard ratio [HR] 2.11; 95% CI 1.40-3.17; P < 0.001) and fourth quartiles (HR 6.55; 95% CI 4.67-9.77; P < 0.001) of carbamylated HDL had increased mortality risk. After adjustment for conventional risk factors, elevated carbamylated HDL was independently associated with all-cause mortality (HR 1.39; 95% CI 1.28-1.52; P < 0.001) as well as with all the cause-specific mortalities. Adding plasma carbamylated HDL level improved the power of the multivariable models for predicting all-cause mortality, with significant increments in C index (from 0.78 to 0.80; P < 0.001), net reclassification index, and integrated discrimination improvement. CONCLUSIONS: Carbamylation of HDL renders HDL dysfunctional, and carbamylated HDL is independently associated with mortality outcomes in patients with type 2 diabetes.
引用
- Lui DTW, Cheung CL, Lee ACH, et al. Carbamylated HDL and Mortality Outcomes in Type 2 Diabetes. Diabetes Care. 2021. PMID: 33402368. doi:10.2337/dc20-2186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。